Day: August 21, 2020

WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the pricing of its upsized initial public offering of 8,684,800 common shares at a public offering price of $20.00 per share. All of the shares are being offered by Kymera. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Kymera, are expected to be approximately $173.7 million. Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,302,720 common shares at the initial public offering price.The shares...

In a Phase 1 study in the U.S., at 7 days after a second dose of 30ug, BNT162b2 elicited SARS-CoV-2–neutralizing geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 times the GMT of the same panel, demonstrating strong immunogenicity in younger and older adults.The companies previously announced that BNT162b2-vaccinated human participants displayed a favorable breadth of epitopes recognized in T cell responses specific to the SARS-CoV-2 spike antigen, and that BNT162b2 demonstrated concurrent induction of high magnitude CD4+ and CD8+ T cell responses against the receptor binding domain (RBD) and against the remainder of the spike glycoproteinAcross...

BNT162b2 induzierte in einer Phase-1-Studie in den USA 7 Tage nach der zweiten 30µg-Dosis mit BNT162b2 in jüngeren Erwachsenen (18-55 Jahre) SARS-CoV-2-neutralisierende geometrische Titer-Mittelwerte (GMT), die dem 3,8-fachen GMT eines Panels aus Rekonvaleszenz-Seren von 38 Patienten entsprachen. In älteren Erwachsenen (65-85 Jahre) induzierte der Impfstoffkandidat einen neutralisierenden GMT, der dem 1,6-fachen GMT des gleichen Panels entsprach und zeigte zudem in jüngeren wie in älteren Erwachsenen eine starke ImmunogenitätWie bereits von den Unternehmen bekanntgegeben, zeigten mit BNT162b2 geimpfte Probanden eine vorteilhaftere Breite an Epitopen, die in T-Zell-Reaktionen erkannt werden, die spezifisch für das SARS-CoV-2-Spike-Antigen sind. Außerdem zeigte BNT162b2 eine gleichzeitige Induktion von hochgradigen CD4+- und CD8+-T-Zellreaktionen...